# ICER and health technology assessment

Source: https://onco.cc/terms/icer-value-assessment/  
OnCo record `icer-value-assessment` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Independent bodies that judge whether a new cancer drug's benefit is worth its price; decisive for coverage outside the US and increasingly inside it.

## Summary

The Institute for Clinical and Economic Review (US, non-governmental) publishes cost-effectiveness reports and 'fair price' benchmarks; NICE (England), CADTH/CDA (Canada), G-BA/IQWiG (Germany), HAS (France), and PBAC (Australia) formally gate reimbursement. Thresholds of $100,000-150,000 per QALY (ICER) or £25,000-35,000 (NICE, since 2 April 2026) versus oncology prices above $200,000 per year drive negotiations and delays.

## Fields

- Kind: Term
- Last checked: 2026-09-08

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Health_technology_assessment
- ICER: https://icer.org
- NICE technology appraisals: https://www.nice.org.uk/guidance

## Connected records

- ideas: [Price a cancer drug by how well it works in each cancer](https://onco.cc/ideas/idea-cost-indication-based-pricing/), [Tie coverage and copays to the ESMO benefit scale](https://onco.cc/ideas/idea-cost-value-scale-in-coverage/)
- terms: [AMNOG (Germany, 2011)](https://onco.cc/terms/amnog/), [EU HTA Regulation (EU) 2021/2282: joint clinical assessments](https://onco.cc/terms/eu-hta-regulation/), [Health technology assessment (HTA), reimbursement and QALYs](https://onco.cc/terms/hta/), [Medicare coverage with evidence development](https://onco.cc/terms/medicare-ced/), [NICE technology appraisal methods (2022)](https://onco.cc/terms/nice-methods/)

---
JSON: https://onco.cc/api/v1/entities/icer-value-assessment.json